No quarterly revenue total was found in ALDEYRA THERAPEUTICS, INC.'s SEC filings.
Aldeyra Therapeutics, Inc. (ALDX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $41.0 million in cash and investments and $458,698 in total debt.
Revenue
—
Net income
$-3.76M
+51.1% vs year-ago quarter
Operating cash flow
$-4.12M
+41.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.06
+53.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
60.36M
+0.3% vs year-ago quarter
Net cash
$40.52M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Concord, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1341235
- Former names
- Aldexa Therapeutics, Inc. (until Mar 4, 2014); Neuron Systems Inc (until Aug 1, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.1M | -$5.9M | -$3.5M | -$6.7M | -$8.0M |
| Net income | -$3.8M | -$5.5M | -$3.5M | -$6.5M | -$7.7M |
| Diluted EPS | -$0.06 | -$0.09 | -$0.06 | -$0.11 | -$0.13 |
| Operating cash flow | -$4.1M | -$4.6M | -$5.1M | -$5.3M | -$7.0M |
| Total assets | $43.4M | $47.5M | $66.5M | $72.1M | $77.8M |
| Total liabilities | $8.2M | $9.7M | $24.3M | $27.8M | $28.6M |
| Stockholders' equity | $35.2M | $37.9M | $42.2M | $44.3M | $49.2M |
| Cash and investments | $41.0M | $45.1M | $65.0M | $70.0M | $75.3M |
| Total debt | $458,698 | $143,447 | $15.5M | $15.6M | $15.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 30, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 14, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Regulation FD disclosure
|
Jun 10, 2026 | Jun 9, 2026 |
All 647 Aldeyra Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.